ArticleBrain & spine2026
Continuous white-light/indocyanine green overlay endoscopy in pituitary adenoma surgery: A prospective feasibility and safety study.
Article in Brain & spine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Intraoperative differentiation between pituitary adenoma (PA) and normal gland tissue remains a key challenge in endoscopic transsphenoidal surgery (ETSS). Indocyanine green fluorescence (ICG-FL) has been proposed as a visual adjunct. Existing data are limited and primarily based on first-generation systems requiring intermittent mode switching. Research question: Is implementation of a second-generation ICG endoscope with continuous white-light/near-infrared (WL/NIR) overlay safe and feasible in routine PA surgery? Materials and methods: This prospective single-center observational study included consecutive patients undergoing ETSS for PA over a 28-month period. A second-generation ICG-FL endoscope with continuous WL/NIR overlay visualization was used throughout tumor resection. Primary endpoints were adverse events related to ICG-administration or device use. Secondary endpoints included surgical complications, short-term endocrine outcome and radiological residual tumor. Results: After screening, 130 patients met inclusion criteria. Continuous WL/NIR overlay was successfully applied in all cases without intraoperative technical failure, dye-related adverse events, or need to revert to white-light-only visualization. Among functional PAs, 75% (52/69) achieved early biochemical remission. At follow-up, 22 patients (17%) had radiologically confirmed residual tumor, while 73 (56%) showed no residual disease. When combined with functional cases not undergoing MRI due to confirmed remission (n = 27), extrapolated gross-total resection was 77%. Discussion and conclusions: Continuous ICG-FL guidance was safe and feasible in routine ETSS for PA, without compromising surgical workflow, anatomical visualization, or requiring conversion to white-light-only endoscopy. Complication rates were consistent with contemporary endoscopic series. Continuous fluorescence provides real-time perfusion information that may facilitate improved tissue differentiation and warrants further comparative evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.